Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology company known for its focus on RNA-targeted drug discovery and development. The company is scheduled to report its next earnings on February 19, 2025, which investors will closely monitor given its current financial performance metrics. The company is scheduled to report its next earnings on February 19, 2025, which investors will closely monitor given its current financial performance metrics.
Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology company known for its focus on RNA-targeted drug discovery and development. The company is scheduled to report its next earnings on February 19, 2025, which investors will closely monitor given its current financial performance metrics.
Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals stands at 58,508 shares. Ionis Pharmaceuticals, based in Carlsbad, California, is a biotechnology company known for its focus on RNA-targeted drug discovery and development.
In other recent news, Ionis Pharmaceuticals has been making significant strides in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) recently approved Ionis's drug TRYNGOLZA for the treatment of Familial Chylomicronemia Syndrome (FCS). The approval signifies Ionis Pharmaceuticals' first solo commercial drug launch. The drug, priced at an annual cost of $595,000, aligns with the anticipated cost for treatments targeting ultra-rare diseases. Piper Sandler and Needham maintained their positive ratings for the company following the approval, projecting $37 million and $27 million respectively in U.S. FCS revenue for the fiscal year 2025. Ionis Pharmaceuticals also reported its third-quarter financial results for 2024, emphasizing non-GAAP financials. These recent developments highlight Ionis Pharmaceuticals' progress and potential in the pharmaceutical industry. The company's focus will initially be on converting patients currently receiving the drug through programs to the commercial version.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.